ArticleAnnals of hematology2023

Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia.

Tongtong Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.